March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Subtenon injection of natural leucocytic interferon-α 2a for treatment of diabetic macular edema. Preliminary results
Author Affiliations & Notes
  • Mauro Cellini
    Ophthalmology Unit - University of Bologna, Bologna, Italy
  • Ernesto Strobbe
    Ophthalmology Unit - University of Bologna, Bologna, Italy
  • Nicole Balducci
    Ophthalmology Unit - University of Bologna, Bologna, Italy
  • Alberto Pazzaglia
    Ophthalmology Unit - University of Bologna, Bologna, Italy
  • Emilio C. Campos
    Ophthalmology Unit - University of Bologna, Bologna, Italy
  • Footnotes
    Commercial Relationships  Mauro Cellini, None; Ernesto Strobbe, None; Nicole Balducci, None; Alberto Pazzaglia, None; Emilio C. Campos, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 406. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mauro Cellini, Ernesto Strobbe, Nicole Balducci, Alberto Pazzaglia, Emilio C. Campos; Subtenon injection of natural leucocytic interferon-α 2a for treatment of diabetic macular edema. Preliminary results. Invest. Ophthalmol. Vis. Sci. 2012;53(14):406.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report the effect of subtenon natural leucocytic interferon-α 2a (IFN-α) on best corrected visual acuity (BCVA) and macular thickness (MT) in diabetic macular edema (DME) refractory to intravitreal injection of bevacizumab and laser grid therapy

Methods: : 20 patients affected by DME received a complete ophthalmic examination including BCVA, indirect ophthalmoscopy and spectral domain ocular coherence tomography (SD-OCT) of the macular region (HRA2, Heidelberg Engineering, Heidelberg, Germany) preoperatively and 1 week, 1 month and 4 months after the third injection of a cycle of 3 subtenon injections/week of IFN-α (1x106 IU/ml)

Results: : Both BCVA and MT significantly improved after 4 months following the last injection (P<0.001, Friedman test). Specifically, SD-OCT images showed a significant reduction in MT after 1 week (501.54µm±25.81 vs 258.61µm±20.39). Later, MT increased after 1 and 4 months, but it was still significantly lower as compared to the baseline value (279.83µm±25.27 and 288.71µm±33.49, respectively). Similarly, BCVA expressed in LogMAR significantly improved after the first week (0.4±0.04 vs 0.31±0.07), was stable after 1 month (0.31±0.08) and it slightly decreased after 4 months (0.32±0.09) but it was still better as compared to the baseline value. No side effects were recorded.

Conclusions: : IFN-α, with its immunomodulatory, antiproliferative and antiangiogenic actions, is effective in improving visual acuity and reducing macular thickness in DME, even if its effect slightly decreases after 4 months from the last injection. In fact, IFN-α enhances the barrier function of retinal microvascular endothelium and inhibits VEGF and other cytokines like IL-8, IL-10 and TGF-β. Subtenon injection is able to reach intravitreal concentrations higher than systemic injection and is well tolerated. Further randomized controlled studies would be useful to assess the effect of IFN-α alone or in combination with other therapies for DME treatment

Keywords: diabetes • edema 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×